The exterior view of the entrance to Merck headquarters in Rahway, New Jersey, on Feb. 5, 2024.
Spencer Platt | Getty Images
Merck on Tuesday beat second-quarter estimates and hiked its revenue outlook, as a slate of new products showed strong growth.Â
But the pharmaceutical giant cut its profit guidance due to a charge tied to its acquisition of biotech company Terns Pharmaceuticals.Â
Merck now anticipates its 2026 revenue will come in between $66.3 billion and $67.3 billion, up from a previous guidance of $65.8 billion and $67 billion.Â
The company also expects adjusted earnings to be between $2.66 and $2.76 per share, which now includes a one-time charge of $5.7 billion, or $2.31 per share, related to the Terns deal. It also includes a $9 billion, or $3.62 per share, charge related to Merck’s acquisition of Cidara Therapeutics in January.Â
That adjusted profit outlook is down from a previous range of $5.04 to $5.16 per…
